PRIMARY NEWBORN DISORDERS

Congenital Hypothyroidism

INFORMATION

Background

The deficiency of thyroid hormones in the neonate has been known since antiquity. Most cases prior to the 20th century were caused by iodine deficiency. Though still a prevalent nutritional disease worldwide, iodine deficiency rarely causes congenital hypothyroidism (CH) in western countries. Permanent neurodevelopmental deficits were known to occur when CH was not recognized and adequately treated by 2 to 3 months of postnatal age. Since the advent of newborn screening for CH in 1973, intellectual disability as a consequence of CH has been virtually eradicated among affected infants detected by screening within the first 2-3 weeks of age. The incidence is approximately 1:4,000 in iodine sufficient populations. The etiology in 70 to 80% of the non-familial cases is unknown. Maternal hypothyroidism may adversely affect the fetus to rarely cause findings of CH, or to be associated with mildly decreased IQ outcomes when maternal hypothyroidism occurs during the first half of pregnancy despite normal fetal and neonatal thyroid function.

Clinical Diagnosis

In greater than 95% of newborn infants with CH, there are no symptoms or signs of CH when the diagnosis is suspected by newborn screening. During the first 2 to 6 months of life, an affected, untreated infant with moderate to severe hypothyroidism may have persistent hyperbilirubinemia, edema, an umbilical hernia, enlarged fontanelles, and an absent, hypoplastic, normal or enlarged thyroid gland; then gradually develops lethargy, poor feeding, macroglossia, hypothermia, constipation, dry and sallow skin, hoarse cry, circumoral pallor, and mottling of the skin

Testing.

There are two newborn screening tests performed in blood to detect hypothyroidism: thyroid stimulating hormone (TSH) and thyroxine (T4). When the thyroid gland is defective, known as Primary CH, TSH values are elevated and T4 values usually are low, although T4 values may be within the normal range in mild CH. Primary CH accounts for > 95% of cases. When there is defective hypothalamic or pituitary regulation of the thyroid gland, known as Central CH, T4 values are low; the TSH values may be low, normal, or mildly elevated.

Serum confirmatory tests usually are limited to 2 tests: TSH and free thyroxine, or FT4 (the small fraction of T4 that is not bound to serum proteins and represents the more biologically relevant measurement). An elevated serum TSH test is diagnostic of primary CH, the most common form of CH. A low serum FT4 with a normal or low TSH is diagnostic of central CH. Infants with central CH should have other tests to evaluate hypothalamic-pituitary function since ACTH/cortisol, growth hormone and/or gonadotropin deficiencies are associated with hypoglycemia (typically within hours of birth), and in male neonates, hypogonadism (micropenis, small testicles, cryptorchidism).

An image of the thyroid gland is often obtained by thyroid ultrasound and/or a radionuclide thyroid scan. These tests determine whether it is enlarged (goiter), absent (athyreosis), small (hypoplasia), or malformed and not in the normal location in the neck (ectopia). In these situations, the infant most often has a permanent form of primary CH. The thyroid gland may be normal in size and in the normal location in the neck (eutopic) on ultrasound, especially in familial causes of CH and transient CH.

Treatment

Treatment of hypothyroidism is relatively uncomplicated. As soon as tests to confirm the diagnosis of CH are obtained, levothyroxine (L-thyroxine) should be started promptly. Central CH may require additional management based on associated findings. Evaluation and monitoring should be performed in conjunction with a pediatric endocrine specialist.

Inheritance

Approximately 15 to 20% of affected infants with CH have one of several inherited forms of CH collectively known as Familial Thyroid Dyshormonogenesis. These diseases are caused by mutations in the enzymes that are required for thyroid hormone synthesis, metabolism and end organ responsiveness, and are inherited as autosomal recessive traits. With similar inheritance patterns the mutations in genes for the synthesis of hypothalamic-pituitary hormones and their receptors infrequently cause CH. There are very rare mutations in genes that regulate thyroid and pituitary gland embryogenesis. The mode of inheritance is unknown. Though not a cause of CH, thyroxine binding globulin (TBG) deficiency is caused by mutations in the gene that is required for the synthesis of this major plasma binding protein for T4. The mode of inheritance usually is X-linked, though autosomal recessive forms of TBG deficiency have been reported.

WORKFLOW

Instruments for Congenital Hypothyroidism

GSP® Instrument

GSP® Instrument

Automated platform for screening of NBS disorders, the GSP® Newborn screening system offers outstanding screening accuracy and reliability, coupled with high efficiency and user-friendliness.
VICTOR2™ D fluorometer

VICTOR2™ D fluorometer

Fluorometer designed for clinical use with all PerkinElmer diagnostic and screening assays based on either time-resolved fluorescence or prompt fluorescence.
AutoDELFIA® immunoassay system

AutoDELFIA® immunoassay system

AutoDELFIA® immunoassay system for prenatal & neonatal screening with fully automated batch-loading
WORKFLOW

Compatible Kits

DELFIA® Neonatal hTSH kit

GSP Neonatal hTSH kit

GSP® Neonatal Thyroxine (T4) kit

AutoDELFIA® Neonatal Thyroxine (T4) kit

ARTICLES & RESOURCES

Related Articles & Resources

ARTICLES & RESOURCES
An innovative approach to sickle cell screening in Uganda – Interview with Charles Kiyaga
Newborn
22 Apr 2021

An innovative approach to sickle cell screening in Uganda – Interview with Charles Kiyaga

An innovative approach to sickle cell screening in Uganda - Interview with Charles Kiyaga
Expanded newborn screening – An interview with Dr. Marianna Messina
Newborn
22 Apr 2021

Expanded newborn screening – An interview with Dr. Marianna Messina

Dr. Marianna Messina discusses her experiences introducing expanded screening to her laboratory in Italy.

PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.

 

GET IN TOUCH

Take the next step

Speak with a sales person

Talk to one of our product experts about the right solutions for you.

Contact us today

View more resources

Explore our articles and resources section for the latest information

Learn More

Read the lastest news

Sign up for our newsletter to find out about the latest news from PerkinElmer and the industry

Sign up
shutterstock_1689772501 1

Find out the latest news

Join our email list for industry news, webinars and the latest information about PerkinElmer’s solutions for Reproductive Health